Image: Public domain | via Wikimedia Commons
Xie Juhua, aged 74, is a director and the largest individual shareholder of Kingfriend, a major pharmaceuticals supplier based in China. Her primary source of wealth stems from the pharmaceutical industry, specifically the production of cardiovascular and anti-tumor drugs. With a real-time net worth estimated at $1.1 billion as of December 4, 2025, Xie Juhua and her family are ranked #2356 on Forbes' 2025 Billionaires list. Her son, Tang Yongqun, chairs Kingfriend.
Information on Xie Juhua's early life is limited, but she has established a significant presence in the pharmaceutical sector. She is a director and the largest individual shareholder at Kingfriend, a pharmaceuticals supplier.
Xie Juhua's wealth is rooted in the success of Kingfriend, a company specializing in the production of cardiovascular and anti-tumor drugs. Her strategic involvement and substantial shareholding have been pivotal in the company's growth and financial achievements.
The main products of Kingfriend include cardiovascular and anti-tumor drugs. Xie Juhua's directorship and ownership have likely influenced the company's strategies in product development, market expansion, and operational efficiency.
Specific information about Xie Juhua's philanthropy is not readily available in the search results. However, philanthropic activities are increasing among wealthy Chinese families. The Tsinghua PBCSF report highlighted that family foundations are focusing on education and healthcare.
Xie Juhua is a director and the largest individual shareholder at Kingfriend, a pharmaceuticals supplier.
Not Available
"Not Available"
Not Available
Not Available
